Introduced by Novo Nordisk, Ozempic and Wegovy both contain the active ingredient semaglutide—primarily utilized for weight management in overweight or obese adults when accompanied by lifestyle changes.
While these medications have been approved by the U.S. Food and Drug Administration, some patients report severe side effects which have led to legal actions against the manufacturer.
Use and manufacturer details
Ozempic and Wegovy have a common creator, Novo Nordisk.
They are part of a treatment plan for those looking to lose weight.
Doctors often prescribe these medications to help with weight management.
Ozempic also plays a key role in controlling Type 2 diabetes.
Wegovy contains the active ingredient semaglutide, similar to what’s found in Ozempic.
This drug got the FDA’s green light for use in adults who are obese or overweight and have at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol.
People take it once a week by injection under their skin.
These drugs target areas of the brain that regulate appetite and food intake.
As such, they can be significant tools in battling excess weight alongside diet changes and exercise.
Health professionals in weight loss clinics may suggest them as part of an overall health plan aimed at reducing medical expenses due to obesity-related issues.